Form 4: Foghorn Therapeutics Director B. Lynne Parshall Acquires Stock Options
SEC Form 4
Director B. Lynne Parshall acquired 16,000 stock options in Foghorn Therapeutics on June 26, 2024, according to a Form 4 filing.
Summary
- B. Lynne Parshall, a director of Foghorn Therapeutics Inc., acquired 16,000 stock options on June 26, 2024.
- The options have an exercise price of $5.52.
- The options become exercisable on June 26, 2025, and expire on June 25, 2034.
- This transaction was reported on a Form 4 filed with the SEC on June 28, 2024.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports a transaction. It's a routine filing and doesn't inherently indicate positive or negative sentiment.
Positives
- A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This is a routine disclosure related to insider transactions, common in publicly traded companies.
Stakeholder Impact
- The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/21/2024 | Date of the Limited Power of Attorney |
| 06/26/2024 | Date of the stock option acquisition. |
| 06/26/2025 | Options become exercisable. |
| 06/25/2034 | Options expiration date. |
| 06/28/2024 | Date the Form 4 was filed. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.